Group 1 - The core viewpoint of the article highlights the significant rise in the stock price of Insilico Medicine (3696.HK) by 14%, reaching HKD 68.7, with a market capitalization approaching HKD 40 billion [1] - Insilico Medicine announced the completion of the first patient dosing in Phase I clinical trials for the MEN2501 project, which is licensed to Menarini Group [1] - As part of the collaboration agreement, Insilico Medicine received a milestone payment of approximately HKD 39 million from Menarini [1] Group 2 - MEN2501, previously known as ISM9682, is a highly differentiated small molecule inhibitor targeting the KIF18A protein, showing significant inhibitory activity against chromosomal instability cancers in preclinical data [1]